Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL

Angioimmunoblastic T cell lymphoma (AITL) is a rare and aggressive lymphoma. Some patients relapsed after initial treatment or did not respond to standard treatment (refractory). Subsequent treatment options are limited and the efficacy is not ideal. This study attempts to explore the possibility of improving the efficacy of immunotherapy combined with chemotherapy and epigenetic regulatory drugs.

Trial Details

NCT ID
NCT07058103
Phase
PHASE2
Sponsor
The Affiliated Hospital of Xuzhou Medical University
Status
RECRUITING
Cancer Type
T-Cell Lymphoma Lymphoma
Interventions
  • tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone
Locations (sample)
  • Xuzhou, Jiangsu, China|34.20442,117.28386

Key Eligibility Criteria

  • Pathological diagnosis of AITL according to WHO classification in 2016, and pathological diagnosis of AITL according to WHO classification in 2016,…
  • Refractory or relapsed after at least one systemic therapy (including chemotherapy, stem cell transplantation)\*;
  • Age ≥18 years old, male or female, ECOGPS≤3 points;
  • Life expectancy exceeds 3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find T-Cell Lymphoma Lymphoma Trials on Trialify →